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Abstract 
Background: Almost everyone experiences low back pain at some point in his or her lives. Low back pain is 
becoming more prevalent in low-income and middle-income countries much more rapidly than in high-income 
countries. The objective of this study was to evaluate the effect of melatonin on pain control and quality of life 
in patients with chronic low back pain. 
Materials and Methods: Sixty patients with low back pain aged 45 and 75 years, with a history of back pain 
more for than 12 weeks and visual analogue scale (VAS) score more than three, who were referred to pain 
clinics of Akhtar Hospitals (Tehran, Iran) during June to August 2018. Patients were randomly assigned to one 
of the melatonin or control groups. Control group received diclofenac sodium 25mg tablet two or three times 
daily and the experimental or melatonin group, in addition to receiving diclofenac sodium 25mg tablet twice a 
day, received melatonin tablet (3mg) 30 to 40 minutes before bedtime for four weeks. Before the beginning of 
the study, at the end of the fourth week, both groups underwent VAS test and the levels of IL-1β and TNF-α 
were measured in these groups and they were asked to complete the quality of life questionnaire. Analysis of 
the data done by using covariance and Shapiro-Wilk tests through SPSS 22. 
Results: Melatonin consumption reduced the pain and level of IL-1β and TNF-α in the experimental group 
compared to the control group (p<0.05). However, use of melatonin did not have a significant effect on 
quality of life (p>0.05). 
Conclusion: In general, it can be stated that use of melatonin, in addition to reducing the pain, reduces the anti-
inflammatory factors in patients with chronic low back pain. Based on the results of this study, melatonin can 
be recommended as a supplement for treatment of chronic low back pain.  
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Introduction 
Pain is the most common physical problem, which 
individuals face with it during their life. As a very 
powerful factor, it affects the quality of life of people 
in different dimensions. Pain is the most common 
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clinical complaint of patients and treatment has been 
considered as one of the oldest treatments for 
humans1. Patients with chronic and severe pain 
gradually isolate themselves from all social activities 
and assume that the boundaries of their world are 
very limited and small. They are more concerned 
with their pain and pay less attention to world around 
them. The world of these people is limited to the 
home, office, pharmacy, frequent admission to 
medical clinics, high costs lead to general fatigue and 
disability, leading family problems2.  
Studies have shown that low back pain leads to 
reduced quality of life in this patients3. several 
therapies have been proposed for the treatment or 
improvement of this disease. Several therapeutic 
methods used for this disease include drug therapy, 
modification in lifestyle, weight loss, muscle 
strengthening, the use of various methods of 
rehabilitation and physiotherapy. However, definitive 
treatment has not been found for this disease4,5,6. 
Melatonin is an indoleamine neurohormone produced 
and secreted by the Pineal gland. Melatonin plays an 
important role in regulating neurological and 
physiological functions of the body such as circadian 
rhythms and reproduction in different seasons. 
Melatonin is secreted at night and is associated with 
sleep, lowering the body temperature and other night-
time events. Melatonin secretion periods are known 
as biological night7. Melatonin is a sedative, 
antioxidant, anti-anxiety, anti-depressant and 
analgesic, its role in regulating circadian rhythms is 
completely associated with its drug properties8. 
Melatonin applies its effect by bonding with two 
types of melatonin receptors, called MT1 and MT29. 
Recent results suggest that antioxidant properties of 
melatonin are much higher than other classical 
antioxidant9,10. Studies have revealed that melatonin 
concentration is significantly lower in patients with 
chronic pain11. Melatonin secretion is also abnormal 
in patients with fibromyalgia and melatonin 
concentration and is much lower in these 
individuals11. As melatonin concentration in blood 
regulates the circadian rhythms, the analgesic effect 
of it occurs at night and evening. In patients who 
removed the gland, circadian rhythms are disrupted12. 
Daily variations in the pain of those who have pain 
for any reason can be justified by this effect of 
melatonin13. Melatonin also has an antinociception 
effect and can block the sensors that stimulate the 
pain12,13. Melatonin also affected on the pain threshold 
and opioid system. For this reason, when naloxone is 
injected, the analgesic effect of melatonin is 
completely neutralized14. Studies have also shown that 
taking melatonin and injection of melatonin into 
intrathecal space can reduce tactile allodynia in 
different models of neuropathic pain15. Melatonin also 
affects the thermal hyperalgesia process. This effect is 
justified by the anti-inflammatory effect of melatonin. 
The anti-inflammatory effect of melatonin has been 
described and investigated in several studies16. 
Melatonin prevents the synthesis of pro-inflammatory 
cytokines such as TNF-α17. However, new studies 
indicate that pro-inflammatory cytokines such as TNF-
α, IL-1 and IL-6 are important mediators in the 
process of allodynia and hyperalgesia, which are the 
most important symptoms of neuropathic pain18.      
In a study, it was found that taking melatonin led to 
secretion and release of β-endorphin in the 
periaqueductal (gray matter around the duct) in mouse. 
ß-endorphin can bind to the opioid receptors μ or κ 
and apply its effect13. Melatonin also applies its 
systemic effect through on the GABAA receptors in 
the spine cords19. some studies suggest that melatonin 
imitates the function of benzodiazepines by binding to 
GABAA receptors20. Several studies have been 
conducted on the analgesic effects of melatonin. These 
studies showed that taking melatonin was effective on 
fibromyalgia, headache, irritable bowel syndrome, 
chronic chest pain, and rheumatoid arthritis21. Low 
back pain can result in severe physical and mental 
disabilities and the therapeutic goals of the disease are 
weight loss, improved function, reduced pain, 
increased range of motion, reduced morning stiffness 
and facilitating the daily activities of life4,5,6. In 
addition, taking melatonin has advantages such as ease 
of use, low side effects, and cost-effectiveness, 
therefore this study was conducted to evaluate the 
effect of melatonin on pain control and quality of life 
in patients with chronic low back pain. 
Methods 
This study was a single-blind clinical trial. The sample 
size was determined to be 23 people with 95% 
confidence level, statistical power of 80%, and 
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standard deviation observed. To obtain sample size, 
Cohen's formula22 was used. Participants were 
patients who referred to pain clinics of Akhtar 
Hospitals (Tehran, Iran) during June to August 2018. 
Out of 100 patients with low back pain for more than 
12 weeks and age of 45 to 75 years who admitted to 
Akhtar Hospital and a VAS score of more than 3, 60 
patients were selected randomly. A total of 30 
subjects were considered in each group (control and 
case groups). The sampling method was simple non-
random. They were randomly divided into two 
groups of 30 patients with control and melatonin. In 
this study, patients were not aware which belonged to 
either of the control or case groups (single-blind). 
Inclusion criteria of study included having at least 
reading and writing skills, having idiopathic low 
back pain in the age range of 45-75 years, walking 
ability, having a pain score of more than 3 based on 
VAS criterion, and having pain for more than 12 
weeks.  Exclusion criteria of study included neural-
muscular diseases, history of accident, and spinal 
cord injury, radicular pains caused by lumbar spine 
disorders, having any rheumatologic disease, history 
of physiotherapy and intra-spinal injections in the 
past 6 months, mental and psychological diseases, 
neoplastic tissues in the spinal cord, infection, 
bleeding tissue, sensory and motor neurological 
disorders, history of surgery in the spinal cord and 
morbid obesity.   
In the study implementation stage, goals of the study 
were described to the patients. It was also announced 
that they could be excluded from the study whenever 
they want and their lack of cooperation with the 
therapist and the hospital did not affect their 
treatment and all patient information would be kept 
confidential. All patients completed and signed the 
informed consent to participate in the study. In 
addition to presenting an educational brochure on the 
use of melatonin, time of follow-up tests, next visit 
and researchers provided face-to-face training for 
both groups on the importance of timely use of the 
drug and the way of taking them correctly. Then, drug 
was provided for them in uniform packages with a 
specific code to be used during first four weeks. 
Subjects were then assigned to control and melatonin 
groups. Control group received diclofenac sodium 
25mg tablet two or three times daily and the 
experimental or melatonin group, in addition to 
receiving diclofenac sodium 25mg tablet twice a day, 
received melatonin tablet (3mg) 30 to 40 minutes 
before bedtime for four weeks (Figure1). Collaborator 
without previous knowledge assessed patients in terms 
of reducing pain and increasing the function before 
treatment and in the fourth week, using visual 
analogue scale (VAS) and patients completed the 
quality of life questionnaire (SF36). The level of IL-1β 
and TNF-α in the blood serum of individuals was also 
measured.  
In data analysis section, mean, standard deviations, 
frequency, tables and charts were used to classify and 
summarize the collected data. To examine the normal 
distribution of the data, Kolmogorov-Smirnov test was 
used.  Analysis of the data done by using covariance 
and Shapiro-Wilk tests through SPSS 22. 
Ethical Criteria in this study was approved with the 
approval of the ethics committee of Shahid Beheshti 
University of Medical Sciences with ethics code of 
IR.SBMU.RETECH.REC.1397.581. 
Results 
In this clinical trial study, 60 patients were assigned 
into control and experimental groups. Clinical 
characteristics of patient groups showed in table 1. 
The mean age of the melatonin group was 51.4 ± 8.4 
years and the mean age of control group was 50.9 ± 
8.1 years, no statistically significant difference was 
found between two groups in this regard (p>0.05). 
Twenty-eight patients were man and the rest of them 
were woman, but no significant difference was found 
between the two groups in terms of gender due to 
matching them in terms of gender (p>0.05). The 
descriptive statistics of the research variables 
Table 1: Number of subjects, age and gender in melatonin and control groups. 
Control Melatonin Parameter 
30 30 Number of subjects 
50.9 ± 8.1 51.4 ± 8.4 age 
15/15 13/17 Men/woman 
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presented in Table 2. The results of Shapiro-Wilk test 
showed that data were normally distributed (p>0.05). 
To analyze the data, covariance analysis was used. 
Table 3 shows the results of covariance analysis to 
compare the quality of life, VAS score, as well as IL-
1β and TNF-α with control of initial levels. Based on 
this table information, after control of the pre-test 
effect (ɳ2=0.001, p=0.856, F (1, 57) =0.33), the 
effect of the group on the VAS scale was statistically 
significant (ɳ2=0.776, p<0.001, F (1, 57)=93.747), 
meaning that there is a significant difference between 
the VAS of the melatonin group and that of control 
group in the post-test. It can be also stated the pain 
level of the experimental group decreased significantly 
as a result of taking melatonin.  
After control of the pre-test effect (ɳ2=0.02, p=0.288, 
F (1, 57)=1.149), the effect of the group on IL-1β was 
statistically significant (ɳ2=0.469, p<0.001, F (1, 
 
 
Figure 1. Modified CONSORT flow diagram. 
 
Table 2: Descriptive indices of pre-test and post-test scores in Melatonin and Control groups. 
variable stage group MEAN± SD s-w Z p 
 Pre-test Melatonin 53.5±0.11 2.1 0.88 
VAS  Control  56.5±0.12 87.0 1.12 
 Post-test Melatonin 7.2±0.14 86.0 1.08 
  Control  44.5±0.11 98.0 0.98 
 Pre-test Melatonin 2.09±0.034 82.0 1.1 
IL-1β  Control  2.08±0.018 93.0 0.97 
 Post-test Melatonin 1.52±0.073 87.0 1.13 
  Control  2.06±0.016 9.0 0.98 
 Pre-test Melatonin 15.52±0.017 96.0 0.94 
TNF-α  Control  15.49±0.017 1.13 0.83 
 Post-test Melatonin 13.08±0.021 1.24 0.75 
  Control  15.47±0.016 0.83 1.12 
 Pre-test Melatonin 71.68±0.18 0.87 1.09 
Quality of life  Control  71.73±0.19 0.99 0.99 
 Post -test Melatonin 72.36±0.19 0.83 1.2 
  Control  72.19±0.19 0.94 0.98 
Abbreviatoin: VAS, Visual Analogue Scale; IL-1β, Interleukin 1 beta; TNF-α, Tumor necrosis factor alpha 
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57)=1.57), meaning that there was a significant 
difference between the groups in terms of IL-1β in 
post-test. It could be stated that the IL-1β in 
experienced group decreased significantly because of 
using melatonin. After control of the pre-test effect 
(ɳ2=0.096, p=0.017, F (1, 57)=6.037), the effect of 
the group on TNF-α was statistically significant 
(ɳ2=0.993, p<0.001, F (1, 57)=87.167), meaning that 
there was a significant difference between the groups 
in terms of TNF-α in post-test. After control of the 
pre-test effect (ɳ2 = 0.199, p<0.001, F (1, 57) 
=14.203), the effect of the group on quality of life 
was not statistically significant (p=0.421). 
Discussion 
The objective of this study was to evaluate the effect 
of melatonin on pain control and quality of life in 
patients with chronic low back pain. Results showed 
that taking melatonin reduced the pain and reduced the 
level of IL-1β and TNF-α in the experimental group 
compared to the control group, while use of melatonin 
did not have a significant effect on quality of life.  
Results showed that intake of melatonin has been 
effective in controlling pain. Studies have indicated 
that melatonin has a higher therapeutic effect than 
amitriptyline23. in a clinical study conducted to 
Table 3: Analysis of covariance model to compare the vas, IL-1β, TNF-α and quality of life in the post-test with the 
control of the initial levels in Melatonin and Control groups. 
Dependent 
variable Source of 
variation 
SS df MS F p ɳ2 
VAS 
Pre-test 016.0 1 016.0 033.0 856.0 001.0 
 
group 747.93 1 747.93 295.197 0.001 776.0 
 
error 084.27 57 475.0    
 
Total corrected 850.120 59     
IL-1β 
Pre-test 098.0 1 098.0 149.1 288.0 02.0 
 
group 309.4 1 309.4 360.50 0.001 469.0 
 
error 877.4 57 086.0    
 
Total corrected 518.9 59     
TNF-α 
Pre-test 063.0 1 063.0 037.6 017.0 096.0 
 
group 167.87 1 167.87 509.8403 0.001 993.0 
 
error 591.0 57 01.0    
 
Total corrected 885.89 59     
Quality of life 
Pre-test 280.13 1 280.13 14.203 0.001 199.0 
 
group 614.0 1 614.0 0.657 0.421 011.0 
 
error 294.53 57 935.0    
 
Total corrected 49.313516 60     
Abbreviatoin: VAS, Visual Analogue Scale; IL-1β, Interleukin 1 beta; TNF-α, Tumor necrosis factor alpha 
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examine the use of melatonin in a cluster headache, 
patients in the melatonin group received 10 mg 
melatonin or placebo for 14 days before bedtime. 
The severity of the pain and the frequency of the 
attack decreased in melatonin group, compared to the 
control group. In addition, the tendency to reduce 
painkillers was shown in the study group, although 
these results were not statistically significant24. In 
another study, patients with cluster headache 
received melatonin 2 mg and no significant 
improvement in pain syndrome was seen compared 
with placebo25 this result might be due to the using 
low dose of melatonin. Results of studies used 
melatonin in the treatment of migraine showed that 
out of six patients; four patients reported reduced 
severity of pain in the morning after using the first 
dose, while the improvement was seen in other two 
patients after using the third dose26. No adverse 
effect was reported on the use of melatonin. Another 
clinical study conducted on 34 patients examined the 
effectiveness of melatonin in preventing migraines. 
Patients received melatonin 3mg 30 minutes before 
bedtime. Results revealed that the use of melatonin in 
32 patients decreased the severity and duration of the 
headache27.   
Our results revealed that use of melatonin in addition 
to reducing the pain reduced the anti-inflammatory 
factors in patients with chronic low back pain. 
Several studies have shown a strong anti-
inflammatory effect of melatonin in in vitro and in 
vivo models. For example, Amstrup et al. 
investigated the effect of melatonin supplementation 
in post-menopausal women with osteopenia, as a 
population characterized by a heightened risk of 
development of osteoporosis.28 A one-year double-
blind randomized placebo-controlled clinical trial 
was conducted on 72 women (56-73 years old), 
supplemented with 1 mg/day, 3 mg/day, or placebo. 
Results collected from melatonin treated groups 
showed an increase in bone mineral density at 
femoral neck and spine levels, in a dose-dependent 
manner. Mahmood et al. showed the anti-
inflammatory effects of melatonin in a dose-
dependent manner in a rat model of chronic 
inflammation, induced by formalin. The study, which 
lasted seven days, was conducted on 54 Sprague-
Dawley rats subdivided into nine groups; these were 
treated with a saline solution, piroxicam, 
dexamethasone and melatonin, respectively29. These 
treatments were administered intraperitoneally 30 
minutes before the induction of inflammation. 
Obtained results showed that all treated groups 
registered a significant inhibition in inflammation 
markers, except for melatonin administered at 0.25 
mg/kg. Melatonin at 5.0 mg/kg induced an inhibition 
percentage in paw thickness comparable to that 
registered in the piroxicam 5.0 mg/kg group. Many 
research articles have reported the anti-inflammatory 
effects of melatonin, and linked these with an 
improvement in neurological function. Farhadi et al. 
showed that in addition to increasing the 16 levels of 
pro-inflammatory cytokines, patients with MS 
presented a decrease in serum levels of melatonin26. 
Kang JC et al. showed that supplementation with 
exogenous melatonin during the inflammatory-
demyelinating process could be useful for the 
improvement of the myelin status of nerve fibers27. El-
Shenawy et al. showed that melatonin, administered 
both systemically (0.5–1.0 mg/kg) and topically (20–
40µg per paw) in rats, exerts anti-nociceptive and anti-
inflammatory effects16. Melatonin was administered 
30 minutes before the induction of acute inflammation, 
through a sub-plantar injection of carrageenan. A more 
recent study reported the beneficial effects of 
melatonin in the treatment of rats affected by 
inflammatory pain induced by intradermal injection of 
complete Freund’s adjuvant (CEA) in rat paw. 
Melatonin or vehicle were administered intraperitoneal 
at doses of 60 mg/kg and 50 mg/kg. The results 
showed a reduction in spinal cord brain-derived 
neurotrophic factor (BDNF) concentration in the 
melatonin-treated group following three days’ 
treatment, compared to the vehicle-treated group. In 
fact, BDNF is involved in the transmission of 
physiological and pathological pain30. Unfortunately, 
despite the positive evidence in rats reported by Laste 
et al.28 that same 20 year Andresen et al.29 published 
the results of a clinical trial on the analgesic effects of 
a single dose of melatonin in a validated human 
inflammatory model. In this case, no significant 
differences were registered between the treated group 
(10 – 100 mg melatonin) and the control group31. 
Several mechanisms have been proposed for the anti-
inflammatory effect of melatonin. These mechanisms 
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include both antioxidative and immunoregulatory 
effects of melatonin. Melatonin and its metabolites 
can neutralize different types of free radicals to 
suppress inflammation in the first steps. It seems that 
potency and mechanisms of antioxidative and 
scavenging of melatonin differ from other classic 
antioxidants. The comparison of scavenging capacity 
of the melatonin with classic antioxidants including 
glutathione (GSH), vitamin C and vitamin E has 
shown that melatonin is up to ten folds more potent 
than others31, 32. Antioxidative properties of 
melatonin embody direct and indirect effects of 
melatonin in the neutralization of free radicals. The 
ability of melatonin to directly neutralize free 
radicals has been indicated in different studies30, 33.  
Limitation of this study was that due to high costs, 
we could not measure other inflammatory factors. 
Therefore, it is suggested that in future studies, the 
effect of melatonin on other inflammatory factors 
should be considered. 
Conclusion 
Finally, melatonin has inherent anticoagulant 
properties mediated through melatonin receptors and 
various neurotransmitter systems, which may further 
explain its positive effects. Although there is no 
reason to consider melatonin as an analgesic drug at 
present time, new clinical studies are needed to gain 
a better understanding of the mechanisms of 
analgesic action and its identification. Given the 
results of this study, melatonin can be recommended 
as a supplement for treatment of chronic low back 
pain. 
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